手术切除的肝门部胆管癌的临床特点及预后因素分析

doi:10.11904/j.issn.1002-3070.2015.03.003

Abstract

Abstract:

Objective To investigate the clinical characteristics and its prognostic factors for hilar cholangiocarcinoma with exairesis.Methods The clinical data of 58 cases of hilar cholangiocarcinoma were retrospectively analyzed.The Kaplan-Meier method was used to estimate the overall survival and disease specific survival rates for these patients.And the factors that may influence the prognosis and survival of patients were analyzed using univariate(log-rank test)and multivariate Cox proportional hazard models.Results The median survival time was 22 months for all patients.The 1-,3-and 5-year survival rates were 76%,40% and 21%,respectively.Univariate analysis showed that preoperative albumin(P=0.002),intraoperative blood loss(P=0.039),surgical method(P=0.006),histologic differentiation(P=0.001),portal vein encroached(P=0.014),surgical margin(P=0.020)were correlated factors for postoperative survival duration.Multivariate analysis by Cox Proportional Hazard Model showed that surgical method(P=0.022),histologic differentiation(P=0.020)were independent prognostic factors for patients with Hilar cholangiocarcinoma excised.Conclusion Low albumin leve,intraoperative blood loss more than 500mL,low degree of tumor differentiation,portal vein encroached,radical surgery,positive surgical margin are risk factors for total survival of Hilar cholangiocarcinoma.

Key words: Hilar cholangiocarcinoma, Survival data analysis, Prognosis factors

CLC Number:

R735.8

LIU Qinlan,YAN Xiaojie,XIA Xueming,BAI Li. Analysis of the clinical characteristics and its prognostic factors for hilar cholangiocarcinoma with exairesis[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 203-207.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2015.03.003

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2015/V29/I3/203

References

1 Soares KC,Kamel I,Cosgrove DP,et al.Hilar cholangiocarcinoma:diagnosis,treatment options,and management[J].Hepatobiliary Surg Nutr,2014,3(1):18-34.
2 黄志强.肝门部胆管癌[J].中华消化外科杂志,2013,12(3):166-169.
3 Zhimin G,Noor H,Jian-Bo Z,et al.Advances in diagnosis and treatment of hilarcholangiocarcinoma-a review[J].Med Sci Monit,2013,19(3):648-656.
4 Eckmann KR,Patel DK,Landgraf A,et al.Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma:a retrospective analysis[J].Gastrointest Cancer Res,2011,4(5-6):155-160.
5 Ramirez-Merino N,Aix SP,Cortés-Funes H.Chemotherapy for cholangiocarcinoma:An update[J].World J Gastrointest Oncol,2013,5(7):171-176.
6 刘斌,崔洪尊,高家森,等.紫杉醇对胆管癌细胞增殖及凋亡的影响[J].实用肿瘤学杂志,2005,18(4):291-293.
7 Izbicki JR,Tsui TY,Bohn BA,et al.Surgical strategies in patients with advanced hilar cholangiocarcinoma(Klatskin tumor)[J].J Gastrointest Surg,2013,17(3):581-585.
8 Friman S.Cholangiocarcinoma-current treatment options[J].Scand J Surg,2011,100(1):30-34.
9 Neuhaus P,Thelen A,Jonas S,et al.Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma[J].Ann Surg Oncol,2012,19(5):1602-1608.
10 Van Gulik TM,Kloek JJ,Ruys AT,et al.Multidisciplinary management of hilar cholangiocarcinoma(Klatskin tumor):extended resection is associated with improved survival[J].Eur J Surg Oncol(EJSO),2011,37(1):65-71.
11 Young AL,Prasad KR,Toogood GJ,et al.Surgical treatment of hilar cholangiocarcinoma in a new era:comparison among leading Eastern and Western centers,Leeds[J].J Hepatobiliary Pancreat Sci,2010,17(4):497-504.
12 Serrablo A,Tejedor L.Outcome of surgical resection in Klatskin tumors[J].World J Gastrointest Oncol,2013,5(7):147-158.
13 Cannon RM,Brock G,Buell JF.Surgical resection for hilar cholangiocarcinoma:experience improves resectability[J].HPB,2012,14(2):142-149.
14 Murakami Y,Uemura K,Sudo T,et al.Prognostic factors after surgical resection for intrahepatic,hilar,and distal cholangiocarcinoma[J].Ann Surg Oncol,2011,18(3):651-658.
15 Dumitrascu T,Chirita D,Ionescu M,et al.Resection for hilar cholangiocarcinoma:analysis of prognostic factors and the impact of systemic inflammation on long-term outcome[J].J Gastrointest Surg,2013,17(5):913-924.
16 Furusawa N,Kobayashi A,Yokoyama T,et al.Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality[J].World J Surg,2014,38(5):1164-1176.
17 Nanashima A,Tobinaga S,Abo T,et al.Experience of surgical resection for hilar cholangiocarcinomas at a Japanese single cancer institute[J].Hepato Gastroenter Ology,2012,59(114):347-350.
18 De Jong MC,Marques H,Clary BM,et al.The impact of portal vein resection on outcomes for hilar cholangiocarcinoma[J].Cancer,2012,118(19):4737-4747.
19 Chen D,Lai JM,Liang LJ,et al.Combination with vascular resection and reconstruction in resection of hilar cholangiocarcinoma[J].Zhonghua Wai Ke Za Zhi,2011,49(7):607-610.

[1]	LIU Chunxun, WANG Peng, ZHAO Haoran, ZHANG Yubao. Mortality trends of biliary tract cancer in China from 1990 to 2019 based on an age-period-cohort model [J]. Journal of Practical Oncology, 2022, 36(4): 299-303.
[2]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[3]	HUANG Yu, LIU Yuqin, DING Gaoheng, GUZANUR·Nyazi, WANG Liangliang, WU Jianjun. Epidemiological characteristics and trend of gallbladder carcinoma in Gansu cancer registration areas from 2009 to 2015 [J]. Journal of Practical Oncology, 2021, 35(3): 193-199.
[4]	ZHU Tong,TAO Xuanchen,SUN Shibo. Research progress of MUC1 and MUC16 in gallblader carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 568-571.
[5]	ZHAO Yun,WEN Feng,ZHAO Xiangxuan,GUO Qiyong. Research progress on TRAIL and its related apoptosis regulating mechanism in cholangiocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 49-52.
[6]	YANG Guang,HE Dongfeng,YANG Yi. The clinical application of single channel and double Chinese-made biliary stent in high biliary malignant obstructive jaundice [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 508-513.
[7]	ZHANG Pengyu, LI Yuanyuan, LI Mingqi, SHI Xuekui, TAO Ji, XIAO Lin, WANG Yaxian. The expression of serous angiopoietin and its affeoh in hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(6): 512-514.
[8]	ZHAN Qi, ZHOU Sheng, LOU Liping. The expression and prognostic value of EGFR,HER2 and HER3 in cholangiocarcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 491-496.

Analysis of the clinical characteristics and its prognostic factors for hilar cholangiocarcinoma with exairesis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments